Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.66 |
| ▸ | LMNA | P02545 | 2/20 | 0.66 |
| ▸ | MAPT | P10636 | 2/20 | 0.66 |
| ▸ | TSHR | P16473 | 2/20 | 0.66 |
| ▸ | BLM | P54132 | 2/20 | 0.66 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.66 |
| ▸ | MEN1 | O00255 | 2/20 | 0.66 |
| ▸ | MPO | P05164 | 1/20 | 0.66 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.66 |
| ▸ | PTPRA | P18433 | 1/20 | 0.65 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
| ▸ | HTR2A | P28223 | 3/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | HTR1A | P08908 | 1/20 | 0.61 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.61 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.61 |
| ▸ | HTR2C | P28335 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL128685 | 1.00 | KMT2A (0.66) | KMT2AKDM4ELMNAMAPTTSHR | |
| SCHEMBL30381542 | 1.00 | KMT2A (0.66) | KMT2AKDM4ELMNAMAPTTSHR | |
| SCHEMBL456668 | 1.00 | KMT2A (0.66) | KMT2AKDM4ELMNAMAPTTSHR | |
| SCHEMBL623336 | 1.00 | KMT2A (0.66) | KMT2AKDM4ELMNAMAPTTSHR | |
| SCHEMBL18029175 | 1.00 | KMT2A (0.66) | KMT2AKDM4ELMNAMAPTTSHR | |
| SCHEMBL11604913 | 0.93 | PTPRA (0.58) | KMT2AKDM4ELMNAMAPTTSHR | |
| SCHEMBL11602575 | 0.93 | PTPRA (0.58) | KMT2AKDM4ELMNAMAPTTSHR | |
| SCHEMBL11602580 | 0.93 | PTPRA (0.58) | KMT2AKDM4ELMNAMAPTTSHR | |
| SCHEMBL195273 | 0.89 | HTR2A (0.73) | KMT2AKDM4ELMNAMAPTTSHR | |
| SCHEMBL21309683 | 0.89 | HTR2A (0.73) | KMT2AKDM4ELMNAMAPTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122094701-A | TLR3 binding bicyclic peptide ligands | — | 2026-05-26 | — | — | CN | claimed |
| WO-2025046244-A1 | TLR3 BINDING BICYCLIC PEPTIDE LIGANDS | BICYCLETX LIMITED (GB) | 2025-03-06 | — | — | WO | claimed |
| EP-4274838-B1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR NK CELLS | BICYCLETX LTD (GB) | 2024-09-25 | — | — | EP | claimed |
| US-11904020-B2 | Bicyclic peptide ligands specific for TREM2 | BICYCLETX LIMITED (GB) | 2024-02-20 | — | — | US | claimed |
| CN-117529489-A | Bicyclic peptide ligands specific for NK cells | 拜斯科技术开发有限公司 | 2024-02-06 | — | — | CN | claimed |
| CN-117337295-A | Bicyclic peptide ligands specific for TREM2 | 拜斯科技术开发有限公司 | 2024-01-02 | — | — | CN | claimed |
| EP-4274838-A2 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR NK CELLS | BicycleTx Limited (GB) | 2023-11-15 | — | — | EP | claimed |
| US-20220296726-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR TREM2 | BICYCLETX LIMITED (GB) | 2022-09-22 | — | — | US | claimed |
| WO-2022148974-A2 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR NK CELLS | BICYCLETX LIMITED (GB) | 2022-07-14 | — | — | WO | claimed |
| EP-4021476-A1 | SYNTHETIC ANTIMICROBIAL PEPTIDES | AJK Biopharmaceutical, LLC (US) | 2022-07-06 | — | — | EP | claimed |
| CN-122094701-A | TLR3 binding bicyclic peptide ligands | — | 2026-05-26 | — | — | CN | disclosed |
| US-20260102461-A1 | PROTEIN SCAFFOLDS FOR DISORDERED REGIONS | AIKIUM INC (US) | 2026-04-16 | — | — | US | disclosed |
| US-20260071243-A1 | BIOLOGICAL PRODUCTION OF TRYPTOPHAN-DERIVED PRODUCTS | UNIV TEXAS (US) | 2026-03-12 | — | — | US | disclosed |
| US-20250387450-A1 | PROTEIN SCAFFOLDS FOR DISORDERED REGIONS | AIKIUM INC (US) | 2025-12-25 | — | — | US | disclosed |
| WO-2025245483-A1 | METHODS AND COMPOSITIONS | FLAGSHIP PIONEERING INNOVATIONS VII, LLC (US) | 2025-11-27 | — | — | WO | disclosed |
| WO-2022081721-A1 | NANOMATERIAL AND METHODS OF USE THEREOF | UNIVERSITY OF CONNECTICUT (US) | 2022-04-21 | — | — | WO | disclosed |
| EP-3983543-A1 | REAGENTS AND METHODS FOR REPLICATION, TRANSCRIPTION, AND TRANSLATION IN SEMI-SYNTHETIC ORGANISMS | The Scripps Research Institute (US) | 2022-04-20 | — | — | EP | disclosed |
| EP-3966201-A1 | THIOSEMICARBAZATES AND USES THEREOF | The Feinstein Institutes for Medical Research (US) | 2022-03-16 | — | — | EP | disclosed |
| EP-3966223-A1 | PEPTIDOMIMETIC AGENTS, SYNTHESIS AND USES THEREOF | The Feinstein Institutes for Medical Research (US) | 2022-03-16 | — | — | EP | disclosed |
| WO-2022047579-A1 | HALOGENATED PSILOCYBIN DERIVATIVES AND METHODS OF USING | MAGICMED INDUSTRIES INC. (CA) | 2022-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11904020-B2 | Bicyclic peptide ligands specific for TREM2 | APP, TIMCC, ADM2 | KMT2A 3481/4885KDM4E 4811/4885LMNA 1950/4885 |
| US-20220296726-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR TREM2 | APP, TIMCC, ADM2 | KMT2A 3481/4885KDM4E 4811/4885LMNA 1950/4885 |
| US-20250387450-A1 | PROTEIN SCAFFOLDS FOR DISORDERED REGIONS | SPPL2B, SPPL2A, CRYZ | KMT2A 4735/4885KDM4E 4295/4885LMNA 1703/4885 |
| US-20260102461-A1 | PROTEIN SCAFFOLDS FOR DISORDERED REGIONS | MAX, CRYZ, STAMBP | KMT2A 4620/4885KDM4E 4268/4885LMNA 948/4885 |
| US-20260071243-A1 | BIOLOGICAL PRODUCTION OF TRYPTOPHAN-DERIVED PRODUCTS | TPH1, TPH2, SLC6A4 | KMT2A 1283/4885KDM4E 3485/4885LMNA 4867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.